BeOne Medicines (ONC) vs Teva Pharmaceutical Industries (TEVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Teva Pharmaceutical Industries (TEVA) has outperformed BeOne Medicines (ONC) over the past year, gaining 94.2% versus a loss of 0.3%. Over five years, TEVA leads with a +305.5% price change compared with -2.3% for ONC. Teva Pharmaceutical Industries is the larger company by market cap ($45.78 billion vs $39.83 billion), about 1.1 times the size, while BeOne Medicines is growing revenue faster (+40.2% vs +4.3%).
On valuation, Teva Pharmaceutical Industries trades at a lower forward P/E (12.7x vs 34.2x for BeOne Medicines). Teva Pharmaceutical Industries converts more of its revenue into profit, with a net margin of 8.2% versus 5.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ONC | TEVA |
|---|---|---|
| Share price | $350.13 | $39.25 |
| Market cap | $39.83B | $45.78B |
| 1-day change | -3.82% | +0.18% |
| YTD return | +15.25% | +25.76% |
| 1-year return | -0.27% | +94.21% |
| 5-year return | -2.32% | +305.48% |
| P/E ratio (TTM) | 62.64 | 65.42 |
| Forward P/E | 34.15 | 12.70 |
| EPS (TTM) | $5.59 | $0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.34B | $17.26B |
| Revenue growth (YoY) | +40.23% | +4.32% |
| Net income (latest FY) | $286.93M | $1.41B |
| Gross margin | 87.49% | 51.79% |
| Operating margin | 8.37% | 12.50% |
| Net margin | 5.37% | 8.17% |
| 52-week high | $385.22 | $40.79 |
| 52-week low | $253.95 | $18.83 |
| Distance from 52-week high | -9.11% | -3.78% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +24.30% | +15.41% |
| Average volume | 388.88K | 5.30M |
| Shares outstanding | 104.92M | 1.17B |
| Employees | 12,000 | 31,173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TEVA has outperformed ONC by 94.5 percentage points over the past year.
- BeOne Medicines grew revenue faster in its latest fiscal year (+40.23% vs +4.32%).
About BeOne Medicines
ONC stock →BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
ONC vs TEVA FAQ
Which is bigger, BeOne Medicines or Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries (TEVA) is larger, with a market capitalization of $45.78B compared with $39.83B for BeOne Medicines (ONC).
Which stock has performed better over the past year, ONC or TEVA?
TEVA returned +94.21% over the past 12 months, compared with -0.27% for ONC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ONC or TEVA?
ONC has the lower trailing P/E at 62.6, versus 65.4 for TEVA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are BeOne Medicines and Teva Pharmaceutical Industries in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.